RT Journal Article SR Electronic T1 Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1457 OP 1460 DO 10.2967/jnumed.120.258434 VO 62 IS 10 A1 Minseok Suh A1 Hyung-Jun Im A1 Hyun Gee Ryoo A1 Keon Wook Kang A1 Jae Min Jeong A1 Sneha Prakash A1 Sanjana Ballal A1 Madhav P. Yadav A1 Chandrasekhar Bal A1 Chang Wook Jeong A1 Cheol Kwak A1 Gi Jeong Cheon YR 2021 UL http://jnm.snmjournals.org/content/62/10/1457.abstract AB 68Ga-NOTA Glu-Urea-Lys (NGUL) is a novel prostate-specific membrane antigen (PSMA)–targeting tracer used for PET/CT imaging. This study aimed to compare performance in the detection of primary and metastatic lesions and to compare biodistribution between 68Ga-NGUL and 68Ga-PSMA-11 in the same patients with prostate cancer. Methods: Eleven patients with metastatic prostate cancer were prospectively recruited. The quantitative tracer uptake was determined in normal organs and in primary and metastatic lesions. Results: 68Ga-NGUL showed significantly lower normal-organ uptake and rapid urinary clearance. The number and sites of detected PSMA-positive primary and metastatic lesions were identical, and no significant quantitative uptake difference was observed. 68Ga-NGUL showed a relatively lower tumor-to-background ratio than 68Ga-PSMA-11. Conclusion: In a head-to-head comparison with 68Ga-PSMA-11, 68Ga-NGUL showed lower uptake in normal organs and similar performance in detecting PSMA-avid primary and metastatic lesions. 68Ga-NGUL could be a valuable option for PSMA imaging.